MedPath

ESBL in Patients Returning to Sweden With Traveller's Diarrhoea

Completed
Conditions
Traveler's Diarrhea
Antibiotic Resistant Strain
Antibiotic Resistant Infection
Interventions
Other: No intervention, observational
Registration Number
NCT03866291
Lead Sponsor
Lund University
Brief Summary

Patients with traveller's diarrhoea frequently harbour Extended Spectrum Betalactamase (ESBL)-producing Enterobacteriaceae (EPE) returning from EPE-endemic areas.

This study investigates to what extent travellers returning to Sweden with traveller's diarrhoea carry ESBL in their stool. The isolates are examined further according to species, phenotype, antibiogram and whole genome sequencing.

Detailed Description

Samples sent to the department of clinical microbiology in Lund, Sweden for culture of salmonella, shigella, yersinia or campylobacter are also cultured selectively for ESBL.

All patients are contacted by mail with the results. ESBL-positive patients are invited to submit further faecal cultures and blood samples during one year follow up time, to investigate how long the patient is colonized with ESBL.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
305
Inclusion Criteria
  • Travellers diarrhoea
  • foreign traveller
Exclusion Criteria
  • foreign traveller but no symptoms

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ESBL carrierNo intervention, observationalThis cohort is followed for a year with additional selective ESBL cultures after 1, 3, 6 and 12 months. In the end of the year a questionnaire is handed in to the study group. Sera is donated after 4-6 weeks and in year.
Non ESBL-carrierNo intervention, observationalNo further rectal cultures. In the end of the year a questionnaire is handed in to the study group. Sera is donated after 4-6 weeks and in year.
Primary Outcome Measures
NameTimeMethod
Proportion ESBL-colonized after one year.1 year

Defined as a Positive ESBL-culture obtained 12 months after travel

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Oskar Ljungquist

🇸🇪

Helsingborg, Skåne, Sweden

© Copyright 2025. All Rights Reserved by MedPath